RT Journal Article
SR Electronic
T1 Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.14.20131128
DO 10.1101/2020.06.14.20131128
A1 Steven Rodriguez
A1 Luxiang Cao
A1 Gregory T. Rickenbacher
A1 Eric G. Benz
A1 Colin Magdamo
A1 Liliana Ramirez Gomez
A1 Eric H. Holbrook
A1 Alefiya D. Albers
A1 Rose Gallagher
A1 M. Brandon Westover
A1 Kyle E. Evans
A1 Daniel J. Tatar
A1 Shibani Mukerji
A1 Ross Zafonte
A1 Edward W Boyer
A1 C. Ron Yu
A1 Mark W. Albers
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131128.abstract
AB Post-infectious anosmias typically follow death of olfactory sensory neurons (OSNs) with a months-long recovery phase associated with parosmias. While profound anosmia is the leading symptom associated with COVID-19 infection, many patients regain olfactory function within days to weeks without distortions. Here, we demonstrate that sterile induction of anti-viral type I interferon signaling in the mouse olfactory epithelium is associated with diminished odor discrimination and reduced odor-evoked local field potentials. RNA levels of all class I, class II, and TAAR odorant receptors are markedly reduced in OSNs in a non-cell autonomous manner. We find that people infected with COVID-19 rate odors with lower intensities and have odor discrimination deficits relative to people that tested negative for COVID-19. Taken together, we propose that inflammatory-mediated loss of odorant receptor expression with preserved circuit integrity accounts for the profound anosmia and rapid recovery of olfactory function without parosmias caused by COVID-19.Competing Interest StatementDan Tatar is the founder of and holds equity in the ADK group. M.W.A. is an inventor on a patent application on the COVID Smell Test.Funding StatementThis work was supported by the NIH DP2 OD006662, the Harvard Blavatanik Sensory Disorder Fund, and the Wilkens Foundation (awarded to M.W.A.), R41 AG062130 (awarded to D.J.T.), a Harvard Catalyst PFDD Fellowship (awarded to S.R).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham (formerly Partners) Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for this study is available with this submission, except raw clinical data with personal health information, or at Synapse (mouse RNA-seq data-syn22161010). https://www.synapse.org/#!Synapse:syn22161010